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ABSTRACT 
Objective   
In an attempt for better treatment of bacterial infections, various semisolid formulations containing 5% 
w/w of norfloxacin were prepared and evaluated for in vitro drug release and in vitro skin permeability 
using dialysis membrane and rat abdominal skin respectively. The in vitro diffusion and permeation 
profile of the prepared formulation was compared with marketed silver sulfadiazine cream 1%, USP 
using model independent approach.  
Methods 
 Various semisolid formulations were prepared with different dermatological bases using 
standard procedures. In vitro diffusion and permeation studies were carried out using Keshary-Chein 
(KC) type diffusion cell using dialysis membrane and rat abdominal skin respectively.   
Results 
The f1 lower than 15 and f2 higher than 50 indicated similarities in the in vitro diffusion and 
permeation profiles of the extemporaneously prepared selected semisolid formulations and marketed 
silver sulfadiazine 1% cream, USP.  
Conclusion 
Amongst all the semisolid formulations prepared, carbopol gel base was found to be most suitable 
dermatological base for norfloxacin, the results obtained for in vitro diffusion, and in vitro skin 
permeation studies are comparable with that of marketed silver sulphadiazine 1% cream, USP.  
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1. INTRODUCTION 
Topical antibiotics can play an important role in prevention and treatment of many 
primary cutaneous bacterial infections commonly seen in dermatological practice like 
localized superficial infections due to surgery, injury and abrasion. Topical antimicrobials 
help in preventing entry of microorganism into wound, which leads to fast healing of wounds. 
Quinolones belongs to synthetic class of antimicrobial agents with potent antimicrobial 
activity which are effective orally and parentally for a wide variety of infectious diseases
2
 .  
Norfloxacin, a broad-spectrum fluroquinolone antibacterial agent, is commonly 
employed in the treatment of urinary and genital tract infections
3
. It is a hydrophilic 
fluroquinolone with unique physiochemical properties such as low water solubility and 
partition coefficient
4, 5
. The objective of the present study was to prepare various topical drug 
delivery systems such as gels and ointments and to evaluate and compare in vitro diffusion 
and permeation profile of the prepared formulation with marketed silver sulfadiazine cream 
1%, USP using model independent approach.  
2. MATERIAL AND METHODS 
Norfloxacin (Pfiscar India Ltd., Murthal, India); Carbopol (Noveon, Mumbai, India). 
All other chemicals used were of analytical grade, UV- Spectrophotometer ( Jasco V-530, 
Jasco Inc., 8649, Commerce Dr., Easton, MD-21601).  
2.1 Preparation of semisolid dosage forms of Norfloxacin 
Various semisolid formulations of norfloxacin (NF) were prepared according to the 
composition given in Table-1 with different dermatological bases using standard procedures. 
In each of the formulations, NF was incorporated at 5% w/w concentration respectively in the 
base with trituration using geometric dilution procedure to obtain homogeneous mass. 
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Table 1: Composition of topical formulations of norfloxacin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CMC: carboxymethyl cellulose; DMSO: dimethyl sulfoxide; HPMC: hydroxylpropylmethyl cellulose; 
NF: norfloxacin; NFL: norfloxacin lactate; PEG: polyethylene glycol; SLS: sodium lauryl sulfate. 
F1- Carbopol gel base  F2- Sodium CMC gel  F3- HPMC gel 
F4- Macrogol gel  F5- Water miscible base  F6- Cold cream 
F7- Simple ointment base F8- Beller’s ointment base F9- Oleagenous base 
 
2.2 In vitro diffusion studies  
In vitro diffusion studies for all formulations were carried out using Keshary-Chein 
(KC) type diffusion cell 
6, 7
. The diffusion cell apparatus was fabricated locally as open-ended 
cylindrical tube with 3.7994cm
2 
area and 100mm height having a diffusion area of 3.8cm
2
. 
1% v/v acetic acid was used as receptor media. The dialysis membrane (25cm
2
) was soaked in 
water for a while, and then for 2h in isotonic phosphate buffer (IPB) solution, pH 7.4 (100ml) 
prior to be mounted on the diffusion cell. A weighed quantity of formulation equivalent to 
25mg of drug was taken on to the dialysis membrane and was immersed slightly in 20ml of 
receptor medium, which was continuously stirred. The entire system was maintained at 
37±1ºC. An aliquot of 2ml were withdrawn at specific time intervals up to 6 h, suitably 
diluted and the NF content was estimated spectrophotometrically at 277.6 nm. After each 
Ingredients↓ Quantity in mg
F1 F2 F3 F4 F5 F6 F7 F8 F9
NF 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
Sodium CMC 5.0
Cetostearyl alcohol 15 15.0
Yellow Beeswax 2.5 5.0 1.0 2.0
Carbopol 940 2.0
Triethanolamine q.s.
Tween 80 5.5
Borax 0.2
Methyl paraben 0.15 0.2 0.3 0.2 0.2 0.2
Propyl paraben 0.05 0.1 0.2 0.1 0.1 10.5 0.1
Sodium metabisulphite 0.1
SLS 2.0
Hard Paraffin 7.0
HPMC 2.0
PEG 4000 50.0
PEG 300 45.0
DMSO 10.5
Isopropyl myristate 8.0
Mineral oil 45.0 30.5
White petrolatum 10.0 30.7 83.0
Propylene glycol 10
Span 60 7.5
Wool fat 10.0
Bees wax 4.8
Glycerine 24.0 10
Water q.s 100 100 100 100 100 66.6
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withdrawal, the diffusion medium was replaced with an equal volume of fresh diffusion 
medium. Average of three determinations was used to calculate the cumulative percent drug 
release at each time interval
8, 9
. 
2.3 In vitro skin permeability studies  
In vitro skin permeation studies were carried out for the best three formulations, which 
exhibited the higher drug release through dialysis membrane using Keshary-Chein (KC) 
diffusion cell 
6, 7 in a similar way as described for In vitro diffusion studies using rat 
abdominal skin. The rat skin was obtained from the abdominal portion of albino rat after 
sacrificing the animal. The hair and fat were removed after treating the skin with  
0.32 mol L
-1
 ammonia solution for 30 minutes
10
 .  The skin was tied to the KC diffusion cell 
(donor cell) such that the stratum corneum side of the skin was in intimate contact with the 
release surface of the formulation in the donor cell
11
. All experiments were carried out in 
triplicate.  
2.4 Comparison of in vitro diffusion and in vitro permeation profiles 
The in vitro diffusion and in vitro skin permeation profiles of the best among the three 
selected formulations in each case was compared for similarity with marketed silver 
sulfadiazine 1% cream, USP. A Model-Independent Approach was used employing a 
difference factor (f1,) and similarity factor (f2) as given in equations 1 and 2, respectively
12, 13
. 
 
(1) 
 
 
(2) 
 
 
Where, Rt and Tt are % dissolved for reference and test formulation at each time point 
and n is the number of time points in dissolution profile. The time intervals used to study the 
f1 and f2 were up to 420 min. 
The f1 value increase proportionally due to the dissimilarity between the two release 
profiles.  If f1 value lies between 0-15 and f2 value of two drug release profiles is between 50 
and 100, then these two drug profiles are considered similar. Value under 50 indicates 
difference between the release profiles. The value of f2 = 50 reflects 10% difference; when 
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value is >50, the difference between R and T is less than 10% 
14
. 
3. RESULTS AND DISCUSSION 
3.1 In vitro diffusion and skin permeability studies  
In the present investigation, in vitro diffusion and permeation were found to be better 
for Carbopol gel formulations (NF1) in comparison to the formulations containing various 
other dermatological bases. The effect of dermatological bases on drug release profiles has 
been well documented
15, 16
. The following cumulative amount of drug diffusion for NF1 at 6 h 
was observed to be 75.03±1.96% and the cumulative amount of drug permeation at the same 
time interval was 16.16±0.75%. 
The comparative release of NF from various formulations is shown in Figure 1. The 
enhanced drug diffusion and drug permeation from the Carbopol gel base may be attributed to 
the presence of pores in the gel which allow relatively free diffusion of the drug to the vehicle 
and lack of over-solubilization of the lipophilic drug in the aqueous vehicle and hence readily 
available for release
17
 .In creams and various oleaginous bases, owing to their biphasic nature, 
partitioning of the drug occurs in aqueous and oil phases which results in the slower release of 
drug. In case of gels, the drug diffusion occurs through the aqueous phase and hence they 
offer a greater drug diffusion and release.  
Figure 1: Comparative in vitro diffusion of different norfloxacin semisolid formulations with 
marketed silver sulfadiazine 1% cream, USP in 6h. 
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The results obtained for in vitro diffusion and in vitro skin permeation studies with NF are 
comparable with that of silver sulphadiazine 1% cream, USP (SS: 71.17±2.10%; 15.95±0.68% 
respectively for in vitro diffusion and skin permeation) available in market.  
The extent of in vitro permeation of drug through skin after 6h was observed to be in 
the range 12.88±0.63 to 16.16±0.75. The extent of permeation of the drug is not sufficient to 
exert a systemic action but it is sufficient to exert a local action at the site of application.  This 
inadequate permeation through the skin is possibly due to a strong affinity of hydrophobic 
drug to the lipophilic stratum corneum or the barrier effect of the latter despite using 
permeation enhancers. However, the diffusion of NF from the three selected formulations was 
in the same order as that from dialysis membrane. 
3.2 Comparison of in  vitro diffusion and in vitro permeation profiles  
  The Comparative in vitro diffusion and in vitro skin permeation of 
selected norfloxacin semisolid formulations with marketed silver sulfadiazine 1% cream, at 6 
h is shown in Figure 2. The values of f1 and f2 for the NF1 as compared to that of the marketed 
silver sulfadiazine 1% cream, USP, were given in Table 2 and Figure 3 and 4. The f1 lower 
than 15 and f2 higher than 50 indicated similarities in the in vitro diffusion and permeation 
profiles.  Thus, the data indicate that the release mechanism of the drug from all the 
formulation follows the same pattern. 
Figure 2:  Comparative in vitro diffusion and in vitro skin permeation of selected norfloxacin 
semisolid formulations with marketed silver sulfadiazine 1% cream, at 6 h. 
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Table 2. Analysis of f1 (difference factor) and f2 (similarity factor) value of 
NF1 and NFL1 with marketed silver sulfadiazine 1% cream, USP. 
Formulation Drug release study f1 f2 
In vitro diffusion 5.82 71.03 
 
NF1 
In vitro skin 
permeation 
9.77 90.51 
 
Figure 3: Analysis of in vitro diffusion profile for f1 (difference factor) and f2 (similarity factor) of 
NF1 with marketed silver sulfadiazine 1% cream, USP. 
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Figure 4:  Analysis of in vitro skin permeation profile for f1 (difference factor) and f2  
(similarity factor) of NF1 with marketed silver sulfadiazine 1% cream, USP. 
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4. CONCLUSION 
The in vitro release characteristics of the prepared topical formulations of norfloxacin 
were quite encouraging and in agreement with marketed Silver Sulfadiazine 1% Cream, USP. 
Amongst all the semisolid formulations prepared, Carbopol gel base was found to be most 
suitable dermatological base for norfloxacin in comparison to various other dermatological 
bases. It also has aesthetic appeal, which other bases lack, an important aspect from patient 
compliance and consumer point of view. 
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